Providing a moist environment

  • Description
  • Benefits
  • Indications
  • In Practice
  • Evidence
  Download product information

Hydrocolloid dressing

  • Provides a moist environment
  • Is waterproof and bacteriaproof
  • Is transparent for better wound monitoring


Algoplaque is a sterile semi-permeable, hydrocolloid dressing:

  • The inner layer is composed of hydrocolloid particles (carboxymethylcellulose) incorporated in an elastomer mesh.
  • The outer backing layer is semi-permeable polyurethane

Mode of action

When in contact with the wound, the hydrocolloid particles absorb exudate gradually, forming a moist gel and creating the optimal conditions for the healing process in terms of moisture, temperature and pH. This gel is non-adherent, which allows the dressing to be removed without damaging the wound.

This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

Benefits for the wound

  • Moist wound healing
  • Absorption and drainage of exudate
  • Atraumatic removal (tangential removal)
  • Bacteria proof (protection from external contaminants)

benefits-for-professionnalBenefits for health professionals

  • Good exudate management
  • Easy to monitor when dressing change necessary (transparent film)
  • Good adhesion, preventing “roll-back” of edges due to friction or incontinence
  • Very conformable
  • Can be used in awkward areas e.g. hip or heel region
  • Convenient (no need for additional dressing retention)

benefits-for-patientBenefits for patients

  • Waterproof for showering and bathing
  • Atraumatic removal (tangential removal)
  • Conformable

Algoplaque is indicated for the local treatment of chronic wounds with healthy surrounding skin (leg ulcers and pressure ulcers) during the granulation stage.

Algoplaque Sacrum and Border are indicated for sacral pressure ulcers or for pressure ulcers in awkward locations (trochanter or heel pressure ulcers) respectively.


Algoplaque should not be used when infection is present or if the peri-wound skin is fragile or damaged.

Instructions for use

  • Clean the wound as per local protocol and rinse with normal saline.
  • If an antiseptic is first used, rinse the wound thoroughly with saline solution before applying Algoplaque.
  • Dry the surrounding skin carefully with a sterile compress.
  • Ensure the size of Algoplaque chosen is large enough to leave 2 to 3 cm of the dressing overlapping the healthy skin around the wound.

  • Remove the protective films and apply Algoplaque to the wound without any tension, making sure not to touch the part with the fingers.
  • Smooth the dressing gently over the wound and more firmly around the edges covering surrounding skin.
  • For Algoplaque Sacrum, apply the dressing with the point down towards the natal (gluteal) cleft. To ensure good adhesion and protection, in case of incontinence, apply as flat as possible.

  • Algoplaque should be changed every 3 to 4 days on average, on an uninfected wound, dependent on exudate level, then replace with Algoplaque Thin (changed every 4 to 6 days) when the wound is at the epithelialisation stage.
  • To remove Algoplaque, stretch the dressing by pulling each side and it will lift slowly and gently from the wound (tangential removal).

Precautions for use

  • In case of highly exuding wounds, the outflow of gelatinous substance around the dressing means that it should be changed.
  • When the dressing is removed, the wound may be covered with a gelatinous coating which will be removed easily simply by cleaning.
  • If the wound becomes infected, the use of Algoplaque should be discontinued.
  • The application of compression therapy is still necessary when treating a venous leg ulcer, despite prescribing Algoplaque
  • Algoplaque should be stored flat, away from heat and moisture.
  • Discard any unused parts of the dressing.
  • Check that the sterility protector is intact before use.
  • Single use sterile individual packaging: re-using a single use dressing may lead to risks of infection.
  • Do not re-sterilise the dressing.

algoplaqueSizes available

  • 10 cm x10 cm
  • 15 cm x15 cm
  • 20 cm x20 cm

For awkward areas

  • 14 cm x14 cm Border
  • 14 cm x16 cm Sacrum

This website is an international website. Some products or sizes can therefore be unavailable in some countries. For more information, please contact us.

Sequential treatment with Calcium Alginate Dressings and Hydrocolloid Dressings Accelerates Pressure Ulcer Healing in Older Subjects: A Multicenter Randomized Trial of Sequential versus Nonsequential Treatment with Hydrocolloid Dressings Alone

Belmin J. et al, JAGS 50:269-274, 2002

  • Objectives: To compare the efficacy of a sequential strategy combining calcium alginate and hydrocolloid dressings of grade III or IV pressure ulcers (PUs) and the efficacy of nonsequential strategy with hydrocolloids alone.
  • Design: An open, randomized, multicenter parallel-group trial.
    • Setting: Twenty geriatrics hospital wards.
    • Participants: One hundred ten older patients with grade III or IV PUs.
    • Intervention: The control strategy consisted of applying hydrocolloid dressings (DuodermE) for 8 weeks; the sequential strategy consisted of applying combined calcium alginate dressings (UrgoSorb) for the first 4 weeks and hydrocolloid dressings (Algoplaque) for the next 4 weeks.
    • Measurements: PU surface areas were measured weekly by ulcer tracing. The endpoints were the mean absolute surface area reduction (SAR) during the 8-week study period and the number of patients achieving a 40% or more SAR (SAR40).
  • Results: Fifty-seven and 53 patients were randomly allocated to sequential and control strategies respectively. Baseline patient characteristics and PU ulcer features at inclusion were similar in the two groups. Mean ± standard deviation SAR was significantly larger in the sequential treatment group (5.4  ± 5.7 cm2 and 7.6 ± 7.1 cm2 at 4 and 8 weeks) than in the control group (1.6 ± 4.9 cm2 and 3.1 ± 7.2 cm2, P < .001). In the sequential treatment group, 68.4% of the patients reached SAR40 at 4 weeks and 75.4% at 8 weeks, proportions significantly larger than in the control group (22.6% and 58.5%, respectively, P < .001). Dressing tolerance was good in both strategies.
  • Conclusions: In grade III or IV PUs, treatment using first calcium alginate dressings and then hydrocolloid dressings and then hydrocolloid dressings promotes faster healing than treatment with hydrocolloid dressings alone.


Last update : June 9, 2015